Synthesis of β-Lactams via Enantioselective Allylation of Anilines with Morita–Baylis–Hillman Carbonates

You Zi; Markus Lange; Philipp Schüler; Sven Krieck; Matthias Westerhausen; Ivan Vilotijevic

doi:10.1055/s-0039-1691570

Synlett, Table of Contents

Synlett 2020; 31(06): 575-580
DOI: 10.1055/s-0039-1691570

cluster

Synthesis of β-Lactams via Enantioselective Allylation of Anilines with Morita–Baylis–Hillman Carbonates

You Zi

^aInstitute of Organic Chemistry and Macromolecular Chemistry, Friedrich Schiller University Jena, Humboldtstrasse 10, 07743 Jena, Germany Email: ivan.vilotijevic@uni-jena.de

,

Markus Lange

^aInstitute of Organic Chemistry and Macromolecular Chemistry, Friedrich Schiller University Jena, Humboldtstrasse 10, 07743 Jena, Germany Email: ivan.vilotijevic@uni-jena.de

,

Philipp Schüler

^bInstitute of Inorganic and Analytical Chemistry, Friedrich Schiller University Jena, Humboldtstrasse 8, 07743 Jena, Germany

,

Sven Krieck

^bInstitute of Inorganic and Analytical Chemistry, Friedrich Schiller University Jena, Humboldtstrasse 8, 07743 Jena, Germany

,

Matthias Westerhausen

^bInstitute of Inorganic and Analytical Chemistry, Friedrich Schiller University Jena, Humboldtstrasse 8, 07743 Jena, Germany

,

Ivan Vilotijevic ∗

^aInstitute of Organic Chemistry and Macromolecular Chemistry, Friedrich Schiller University Jena, Humboldtstrasse 10, 07743 Jena, Germany Email: ivan.vilotijevic@uni-jena.de

› Author Affiliations

Abstract

All articles of this category

Published as part of the ISySyCat2019 Special Issue

Abstract

Enantioenriched β-lactams are accessed via enantioselective allylation of anilines with Morita–Baylis–Hillman carbonates followed by a base-promoted cyclization. The resulting 3-methyleneazetidin-2-ones are amenable to diastereoselective functionalization to produce analogues of biologically active β-lactams. The use of nearly equimolar quantities of the starting materials make this method efficient and straightforward.

Key words

β-lactams - allylic substitution - allylation - Lewis base catalysis

Full Text

References

References and Notes
1 González-Bello C, Rodríguez D, Pernas M, Rodríguez Á, Colchón E. J. Med. Chem. 2019; in press; DOI:
2 Yimer EM, Hishe HZ, Tuem KB. Front. Neurosci. 2019; 13: 236

3a O’Boyle NM, Carr M, Greene LM, Bergin O, Nathwani SM, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ. J. Med. Chem. 2010; 53: 8569
3b O’Boyle NM, Greene LM, Bergin O, Fichet J.-B, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ. Bioorg. Med. Chem. 2011; 19: 2306
3c Zhou P, Liang Y, Zhang H, Jiang H, Feng K, Xu P, Wang J, Wang X, Ding K, Luo C. Eur. J. Med. Chem. 2018; 144: 817

4 Pitts CR, Lectka T. Chem. Rev. 2014; 114: 7930

5a Zi Y, Lange M, Schultz C, Vilotijevic I. Angew. Chem. Int. Ed. 2019; 58: 10727
5b Lange M, Zi Y, Vilotijevic I. J. Org. Chem. 2019; in press; DOI:

6a Ma G.-N, Jiang J.-J, Shi M, Wei Y. Chem. Commun. 2009; 5496
6b Basavaiah D, Reddy BS, Badsara SS. Chem. Rev. 2010; 110: 5447
6c Wei Y, Shi M. Chem. Rev. 2013; 113: 6659
6d Wei Y, Shi M. Acc. Chem. Res. 2010; 43: 1005
6e Xie P, Huang Y. Org. Biomol. Chem. 2015; 13: 8578
6f Tang Q, Tu A, Deng Z, Hu M, Zhong W. Chin. J. Org. Chem. 2013; 33: 954

7a Rajesh S, Banerji B, Iqbal J. J. Org. Chem. 2002; 67: 7852
7b Kim J.-M, Kim S.-H, Kim S.-H, Kim J.-N. Bull. Korean Chem. Soc. 2008; 29: 1583
7c Wang X, Meng F, Wang Y, Han Z, Chen YJ, Liu L, Wang Z, Ding K. Angew. Chem. Int. Ed. 2012; 51: 9276
7d Wang Y, Liu L, Wang D, Chen Y.-J. Org. Biomol. Chem. 2012; 10: 6908
7e Wang Y, Zhang T, Liu L. Chin. J. Chem. 2012; 30: 2641
7f Wang X, Guo P, Han Z, Wang X, Wang Z, Ding K. J. Am. Chem. Soc. 2013; 136: 405
7g Zhu L, Hu H, Qi L, Zheng Y, Zhong W. Eur. J. Org. Chem. 2016; 2139
7h Sundararaju B, Achard M, Bruneau C. Chem. Soc. Rev. 2012; 41: 4467

8a Shi M, Xu YM. Angew. Chem. Int. Ed. 2002; 41: 4507
8b Matsui K, Takizawa S, Sasai H. J. Am. Chem. Soc. 2005; 127: 3680
8c Masson G, Housseman C, Zhu J. Angew. Chem. Int. Ed. 2007; 46: 4614
8d Shi Y.-L, Shi M. Eur. J. Org. Chem. 2007; 2905
8e Declerck V, Martinez J, Lamaty F. Chem. Rev. 2009; 109: 1

9a Li J, Wang X, Zhang Y. Tetrahedron Lett. 2005; 46: 5233
9b Zhang T.-Z, Dai L.-X, Hou X.-L. Tetrahedron: Asymmetry 2007; 18: 1990
9c Sun W, Ma X, Hong L, Wang R. J. Org. Chem. 2011; 76: 7826
9d Ma G, Sibi MP. Org. Chem. Front. 2014; 1: 1152
9e Yao L, Wang C.-J. Adv. Synth. Catal. 2015; 357: 384
9f Kamlar M, Císařová I, Hybelbauerová S, Veselý J. Eur. J. Org. Chem. 2017; 1926
9g Dočekal V, Šimek M, Dračínský M, Veselý J. Chem. Eur. J. 2018; 24: 13441
9h Li Z, Frings M, Yu H, Raabe G, Bolm C. Org. Lett. 2018; 20: 7367
9i Li Z, Frings M, Yu H, Bolm C. Org. Lett. 2019; 21: 3119

10 Bordwell FG, Algrim DJ. J. Am. Chem. Soc. 1988; 110: 2964

11a Bakthadoss M, Srinivasan J, Selvakumar R. Aust. J. Chem. 2014; 67: 295
11b Kim JN, Lee HJ, Lee KY, Gong JH. Synlett 2002; 173

12a Chen H.-Y, Patkar LN, Ueng S.-H, Lin C.-C, Lee AS.-Y. Synlett 2005; 2035
12b Lee CG, Lee KY, Lee S, Kim JN. Tetrahedron 2005; 61: 1493
12c Lee C.-G, Gowrisankar S, Kim J.-N. Bull. Korean Chem. Soc. 2005; 26: 481
12d Kim S.-C, Gowrisankar S, Kim J.-N. Bull. Korean Chem. Soc. 2005; 26: 1001
12e Pathak R, Madapa S, Batra S. Tetrahedron 2007; 63: 451
12f Gowrisankar S, Lee HS, Kim JM, Kim JN. Tetrahedron Lett. 2008; 49: 1670

13a Du Y, Han X, Lu X. Tetrahedron Lett. 2004; 45: 4967
13b Lin A, Mao H, Zhu X, Ge H, Tan R, Zhu C, Cheng Y. Adv. Synth. Catal. 2011; 353: 3301
13c Pei C.-K, Zhang X.-C, Shi M. Eur. J. Org. Chem. 2011; 4479
13d Liu TY, Xie M, Chen YC. Chem. Soc. Rev. 2012; 41: 4101
13e Zhao M.-X, Chen M.-X, Tang W.-H, Wei D.-K, Dai T.-L, Shi M. Eur. J. Org. Chem. 2012; 3598
13f Putaj P, Tichá I, Císařová I, Veselý J. Eur. J. Org. Chem. 2014; 6615

During the preparation of this manuscript, two independent reports describing similar reactions of anilines and MBH carbonates were published. These methods use 10 mol% of β-isocupreidine as the catalyst in toluene (1.5 equiv of carbonate) and 20 mol% of (DHQD)₂AQN as the catalyst in p-xylene in the presence of CaF₂ (2 equiv of carbonate). In comparison, our protocol uses a lower catalyst loading and avoids the use of superstoichiometric quantities of MBH carbonate, as is the case in these two previous reports, see:

14a Formánek B, Šimek M, Kamlar M, Císařová I, Veselý J. Synthesis 2019; 51: 907
14b Zhao S, Chen Z.-L, Rui X, Gao M.-M, Chen X. Synlett 2019; 703

15a Puylaert P, van Heck R, Fan Y, Spannenberg A, Baumann W, Beller M, Medlock J, Bonrath W, Lefort L, Hinze S. Chem. Eur. J. 2017; 23: 8473
15b Schömberg F, Zi Y, Vilotijevic I. Chem. Commun. 2018; 54: 3266
15c Zi Y, Schömberg F, Seifert F, Görls H, Vilotijevic I. Org. Biomol. Chem. 2018; 16: 6341

16 Enantioselective Allylation of Anilines; General Procedure Carbonate 7 (1 equiv), aniline 8 (1.1 equiv) and (DHQD)₂AQN (10 mol%) were added to a vial containing a stir bar. The vial was evacuated and refilled with nitrogen 3 times. The reaction mixture was then stirred at room temperature after adding cyclohexane (0.4 M). After completion of the reaction, the solvent was removed under reduced pressure. The crude residue was purified by column chromatography (eluent: 5% ethyl acetate in petroleum ether). Methyl 2-{[(4-Chlorophenyl)amino](phenyl)methyl}acrylate (9a) Yield: 28 mg (94%); pale yellow oil; 93:7 er (determined by HPLC analysis) [Phenomenex Lux Cellulose-1, n-hexane/i-PrOH = 95:5, 1.0 mL/min, λ = 253 nm, t _R (major) = 18.73 min, t _R (minor) = 14.92 min]. ¹H NMR (300 MHz, CDCl₃): δ = 7.48–7.27 (m, 5 H), 7.18–7.04 (m, 2 H), 6.57–6.44 (m, 2 H), 6.40 (s, 1 H), 5.92 (s, 1 H), 5.39 (s, 1 H), 4.24 (s, 1 H), 3.72 (s, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ = 166.58, 145.23, 140.21, 139.80, 129.07, 128.88, 128.01, 127.51, 126.37, 122.60, 114.63, 59.13, 52.06.
17 Cyclization to β-Lactams 10; General Procedure To a solution of 9 (1.0 equiv) in toluene was added Sn[HMDS]₂ (1.5 equiv). The mixture was refluxed for 2 h and the solution then cooled and concentrated. The residue was purified by flash chromatography on silica gel (eluent: 5% ethyl acetate in petroleum ether) to afford the desired product. (R)-1-(3-Methoxyphenyl)-3-methylene-4-phenylazetidin-2-one (10i) Yield: 14 mg (85%); white solid. IR (ATR): 2927, 2360, 1743, 1597, 1492, 1454, 1369, 1249, 1114, 848, 752 cm^–1. ¹H NMR (400 MHz, CDCl₃): δ = 7.46–7.32 (m, 5 H), 7.17 (t, J = 8.1 Hz, 1 H), 7.06 (t, J = 2.2 Hz, 1 H), 6.84 (dd, J = 8.0, 1.9 Hz, 1 H), 6.63 (dd, J = 8.2, 2.5 Hz, 1 H), 5.86 (t, J = 1.9 Hz, 1 H), 5.41 (d, J = 1.6 Hz, 1 H), 5.19 (d, J = 1.6 Hz, 1 H), 3.77 (s, 3 H). ¹³C NMR (101 MHz, CDCl₃): δ = 161.01, 160.13, 149.77, 138.68, 136.45, 129.92, 129.10, 128.81, 126.61, 111.01, 110.11, 109.41, 103.00, 63.72, 55.28. HRMS (EI): m/z [M]⁺ calcd for C₁₇H₁₅NO₂: 265.1103; found: 265.1094.
18 Reduction to β-lactams 11; General Procedure To a degassed ethyl acetate solution of 10 (1 equiv) was added (10 mol%) Pd/C and the reaction flask was furnished with a H₂ balloon. After stirring for 30 min, the reaction mixture was filtered over Celite and evaporated. The crude residue was purified by flash column chromatography (eluent: 5% ethyl acetate in petroleum ether). (3S,4S)-1-(4-Chlorophenyl)-3-methyl-4-(naphthalen-2-yl)azetidin-2-one (11x) Yield: 25 mg (98%); white solid. IR (ATR): 2974, 1728, 1597, 1492, 1381, 1365, 1161, 1091, 813, 744 cm^–1. ¹H NMR (300 MHz, CDCl₃): δ = 7.92–7.77 (m, 3 H), 7.73–7.67 (m, 1 H), 7.53 (dt, J = 6.3, 3.4 Hz, 2 H), 7.37–7.28 (m, 3 H), 7.25–7.16 (m, 2 H), 5.35 (d, J = 6.0 Hz, 1 H), 3.80 (qd, J = 7.6, 5.9 Hz, 1 H), 0.93 (d, J = 7.6 Hz, 3 H). ¹³C NMR (75 MHz, CDCl₃): δ = 168.44, 136.28, 133.18, 132.13, 129.16, 128.80, 128.72, 127.89, 127.82, 126.66, 126.45, 126.22, 124.36, 118.34, 58.74, 49.79, 9.79. HRMS (EI): m/z [M]⁺ calcd for C₂₀H₁₆ClNO: 321.0920; found: 321.0916.

Supplementary Material

Supporting Information